Frequently Asked Questions
The market is segmented based on , By Therapy (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Combination Therapy, and Others), Medicine Type (Chemotherapy Drugs and Vaccines), Route of Administration (Parenteral, Oral, and Others), Cancer Type (Melanoma, Mast Cell Cancer, Lymphoma, Mammary and Squamous Cell Cancer, and Others), Species Type (Cat, Dog, and Others), End User (Veterinary Hospitals and Clinical Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) – Industry Trends and Forecast to 2031.
.
The Global Pet Cancer Therapeutics Market size was valued at USD 283.86 USD Million in 2023.
The Global Pet Cancer Therapeutics Market is projected to grow at a CAGR of 9.1% during the forecast period of 2024 to 2031.
The major players operating in the market include AB Science (France), Elanco (U.S.), Candel Therapeutics (Canada), NIPPON ZENYAKU KOGYO CO. LTD. (Japan), Rhizen Pharmaceuticals AG (Switzerland), Virbac Corporation (France), Pfizer Inc. (U.S.), VetDC (U.S.), Boehringer Ingelheim International GmbH (Germany), Karyopharm (U.S.), VETCO (U.S.), ELIAS Animal Health (U.S.), Vivesto AB (Sweden), Torigen Pharmaceuticals Inc. (U.S.), and Zoetis Services LLC (U.S.).
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
